- Home
- BSBK vs KLRS Comparison
BSBK vs KLRS Comparison
Compare BSBK & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BSBK | KLRS |
|---|---|---|
| Founded | 1893 | 2019 |
| Country | United States | United States |
| Employees | 57 | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.9M | 113.0M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BSBK | KLRS |
|---|---|---|
| Price | $9.06 | $4.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 9.5K | ★ 613.4K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 200.00 | 75.70 |
| EPS | ★ 0.12 | N/A |
| Revenue | N/A | ★ $165,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $151.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.10 | $2.36 |
| 52 Week High | $9.55 | $11.88 |
Technical Indicators
Market Signals| Indicator | BSBK | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 56.47 | 50.76 |
| Support Level | $8.86 | $3.96 |
| Resistance Level | $9.24 | $4.40 |
| Average True Range (ATR) | 0.18 | 0.31 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 38.63 | 78.10 |
Price Performance
Historical ComparisonAbout BSBK Bogota Financial Corp.
Bogota Financial Corp is a New Jersey-based bank. It offers personal and business banking services such as savings, certificates of deposits, online banking, loans, and many more. The Bank generally grants residential, commercial, and consumer loans to, and accepts deposits from, customers in New Jersey. The Company operates one reportable segment of business, retail banking. Through its community banking segment, the Company provides a broad range of retail and commercial banking services.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.